DNA Aptamers that Specifically Bind the Soluble Interleukin-6 Receptor

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses the invention of specific DNA aptamers that selectively bind to the human soluble interleukin-6 receptor (sIL-6R). These aptamers can be used as diagnostic and/or therapeutic agents for the detection, prevention, or treatment of inflammatory diseases, cancer, and infections. The DNA aptamers are designed to have high specificity and affinity toward sIL-6R, offering an alternative to traditional antibody-based approaches, potentially with fewer side effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Diagnosis of diseases associated with abnormal sIL-6R or IL-6R levels, such as autoimmune and inflammatory conditions.
• Therapeutic treatment of diseases where IL-6/sIL-6R signaling is pathogenic, including rheumatoid arthritis, sepsis, asthma, Crohn's disease, multiple sclerosis, breast cancer, multiple myeloma, and HIV infection.
• Targeted drug delivery by coupling the aptamer to therapeutic agents, enabling selective introduction into cells expressing the target receptor.
• Development of diagnostic assays or biosensors for detecting sIL-6R in biological samples, such as blood tests for inflammation or cancer markers.
• Use in research to study interleukin-6 signaling pathways and receptor interactions.

BenefitsContent extracted from patent full text and abstract with AI.

• High specificity and affinity for the soluble and membrane-bound IL-6 receptor, enhancing diagnostic and therapeutic accuracy.
• Lower immunogenicity compared to antibodies, reducing the risk of immune-related side effects.
• Potential for reduced side effects compared to antibody-based therapies, like monoclonal antibodies, which are currently used for similar indications.
• Chemical stability, ease of synthesis, and storage, resulting in cost-effective and scalable production.
• Versatility, as the aptamers can be modified (e.g., conjugated to drugs or dyes) for various diagnostic, therapeutic, or research applications.
• Non-competitive binding allows flexible usage as it does not disrupt natural ligand (IL-6) binding, which can be advantageous in certain diagnostic or therapeutic strategies.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to aptamers specifically binding to a target molecule. The aim of the invention is to provide diagnostic and/or therapeutic agents for use in the recognition and/or prevention or treatment of inflammatory processes, of cancerous diseases and of infections. To achieve this aim, the invention provides a DNA aptamer that specifically binds to the human soluble interleukin-6 receptor (sIL-6R), said aptamer comprising the sequence GGGNGGGHGGGWGGG however with the exception of GGGTGGGTGGGTGGGT. N = A, T, TT or TTT, H = A, C or T, and W = A or T.